Study of how food affects ECC4703 in healthy adults
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests how taking the study drug ECC4703 with or without food affects its levels in the body, and how well the body absorbs it. It helps find the best way to take the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old
- Have a body mass index (BMI) between 18.0 and 32.0 and weigh at least 110 lbs (men) or 99 lbs (women)
- Be generally healthy, with no major medical conditions
- Not be pregnant, breastfeeding, or planning pregnancy during the study and for 3 months after
- Agree to use effective contraception if you can become pregnant or get someone pregnant
- Not take any medications (except specific allowed ones) for 2 weeks before starting the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This study tests how two different tablet versions of the study drug BGB-58067 enter the body and how food affects the drug. Healthy volunteers take the drug to help understand the best way to give it in future trials.
This early-phase study tests how a new drug (ECC4703) works in the body when taken with two other common medications (sulfasalazine and pitavastatin). Healthy volunteers are needed to help researchers understand potential drug interactions and safety.
This early-stage study checks if a new medicine called HEC169584 is safe for people and how it moves through the body. It looks for healthy volunteers to take part.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This trial tests how different versions of the drug elecoglipron are absorbed by the body and if they are safe. It is for healthy people to help find the best way to take the medicine.
Hear when a new Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.